Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Tolerability of Adjunctive KarXT in Schizophrenia
NCT05304767Phase 3Completed
- Sponsor
- Karuna Therapeutics
- Start
- Mar 2022
- Primary completion
- Mar 2026
- Countries
- 4
01
Overview
A Phase 3 trial of xanomeline in schizophrenia, sponsored by Karuna Therapeutics. Started Mar 2022; status: completed.
02
Drugs
xanomeline
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05304767.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05304767.